Genome Biologics is a Biotherapeutics company headquartered in Germany with a strong background and proven track record in in silico drug screening, in vivo preclinical drug testing and state-of-the-art transgenic technologies.

Established by industrial and academic experts and supported by leading academic institutions, CROs and the pharmaceutical industry, Genome Biologics combines the power of Artificial Intelligence based machine learning with big data, genomics and molecular science to rapidly identify drug-disease matches and generate complex in-vivo disease models.

GENIMAPS®

GENIMAPS®

GENIMAPS® is a novel AI cloud-based multi-omics database, developed to screen compounds for gene interaction. GENIMAPS® exploits pattern recognition and machine real-time learning alghorithms to overlay compounds databases with massive datasets of disease and disease-subtype signatures to make molecular matches and identify candidate compounds with real efficacy and specificity. Learn more about GENIMAPS®

Read more
GENISYST®

GENISYST®

GENISYST® addresses the inefficiencies of current preclinical testing - which is an expensive and time-consuming barrier in drug development or academic research. GENISYST® can create up to 50 single genetic modifications or 20 multigenic combinatorial gene modifications, representing disease subtypes in a single animal in 6-8 weeks, as opposed to several years using conventional technologies. GENISYST® is the missing link in translation from preclinical to clinical studies. Find our more about GENISYST®

Read more
GENIMAPS®-GENISYST®

GENIMAPS®-GENISYST®

GENIMAPS®-GENISYST® drug discovery and repurposing platform allows an immediate and accelerated in-silico identification and evaluation of candidate compounds in small and large animal translational models, thus quickly identifying effective treatments for some of the worlds’ worst and rarest diseases and bringing them to phase 2b or 3 clinical trials as fast as within 3 - 6 months. The GENIMAPS®-GENISYST® system is a disruptive technology platform that redefines the way we target diseases, identify and test drugs. Find out more about this unique offering

Read more

At the heart of Genome Biologics lie two innovative proprietary and patented technologies:

  • Gene-Disease Integrative Drug-Disease Mapping (GENIMAPS®): an in-silico proprietary drug discovery platform, and;
  • Gene-Disease-Integrative-Systems-Transgenesis (GENISYST®): a patented multigenic and multiplexed in-vivo preclinical testing platform

Got a project? Start working with us today!